UROLOGIX INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-10: Form 8-K; Period of report 2014-11-06; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2014-11-05: Form 8-K; Period of report 2014-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-09-25: Form 8-K; Period of report 2014-09-22; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2014-08-20: Form 8-K; Period of report 2014-08-19; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-10 | 8-K | 2014-11-06 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Urologix, Inc. (the “Company”) held its 2014 Annual Meeting of Shareholders (the “Annual Meeting”) on November 6, 2014 at the Sheraton Minneapolis West, 12201 Ridgedale Drive, Minnetonka, Minnesota, beginning at 4:00 p.m., local time. | urologix144045_8k.htm |
| 2014-11-05 | 8-K | 2014-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on November 4, 2014 disclosing material non-public information regarding the Company’s results of operations for the first fiscal quarter of fiscal year 2015 ended September 30, 2014. | urologix143985_8k.htm |
| 2014-09-25 | 8-K | 2014-09-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 22, 2014, the Compensation Committee of the Board of Directors (the “Committee”) of Urologix, Inc. (the “Company”) recommended, and the Board of Directors approved, annual target compensation amounts for Gregory J. Fluet, the Company’s Chief Executive Officer, and Lisa A. Ackermann, the Company’s Executive Vice President, Sales and Marketing (collectively, the “Executives”). | urologix143446_8k.htm |
| 2014-08-20 | 8-K | 2014-08-19 | 2.02 Results of Operations and Financial Condition | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on August 19, 2013 disclosing material non-public information regarding the Company’s results of operations for the fourth fiscal quarter and fiscal year 2014 ended June 30, 2014. | urologix143064_8k.htm |
| 2014-08-19 | 8-K | 2014-08-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 13, 2014, Brian J. Smrdel, the Company’ s Chief Financial Officer, tendered his resignation to the Company effective as of that date. | urologix143074_8k.htm |
| 2014-05-07 | 8-K | 2014-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on May 6, 2014 disclosing material non-public information regarding the Company’s results of operations for the third fiscal quarter of fiscal year 2014 ended March 31, 2014. | urologix141724_8k.htm |
| 2014-04-16 | 8-K | 2014-04-10 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on April 10, 2014 disclosing material non-public information regarding the Company’s preliminary revenue for the third quarter of fiscal year 2014 ended March 31, 2014 and the Company’s preliminary cash balance as of March 31, 2014. 8.01 Through the press release issued on April 10, 2014 furnished with this Form 8-K as Exhibit 99.1, the Company also announced a strategic restructuring of its organizational infrastructure. | urologix141405_8k.htm |
| 2014-03-27 | 8-K | 2014-03-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 21, 2014, Urologix, Inc. (the “Company”) received a letter from Medtronic, Inc. (“Medtronic”). | urologix141108_8k.htm |
| 2014-02-05 | 8-K | 2014-02-04 | 2.02 Results of Operations and Financial Condition | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on February 4, 2014 disclosing material non-public information regarding the Company’s results of operations for the second fiscal quarter of fiscal year 2014 ended December 31, 2013. | urologix140417_8k.htm |
| 2014-02-04 | 8-K | 2014-01-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 On January 30, 2014, Urologix, Inc. (the “Company”) entered into a Third Amendment to Loan and Security Agreement (the “Third Amendment”) with Silicon Valley Bank (“SVB”). | urologix140401_8k.htm |
| 2014-01-10 | 8-K | 2014-01-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 On January 9, 2014, Urologix, Inc. (the “Company”) entered into a Second Amendment to Loan and Security Agreement (the “Second Amendment”) with Silicon Valley Bank (“SVB”). | urologix140077_8k.htm |
| 2014-01-08 | 8-K | 2014-01-08 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on January 8, 2014 disclosing material non-public information regarding the Company’s preliminary revenue for the second fiscal quarter of fiscal year 2014 ended December 31, 2013 and the Company’s preliminary cash balance at December 31, 2013. 8.01 Through the press release issued on January 8, 2014 furnished with this Form 8-K as Exhibit 99.1, the Company also announced a strategic restructuring and withdrew its previously issued fiscal year 2014 revenue guidance. | urologix140047_8k.htm |